Revolution Ebit vs Research Development Analysis

RVMDW Stock

0.36 0.04 11.18%

Revolution Medicines, financial indicator trend analysis is much more than just breaking down Revolution Medicines, prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Revolution Medicines, is a good investment. Please check the relationship between Revolution Medicines, Ebit and its Research Development accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines, Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Revolution Medicines, Ebit account and Research Development. At this time, the significance of the direction appears to have pay attention.

The correlation between Revolution Medicines,'s Ebit and Research Development is -0.93. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Research Development in the same time period over historical financial statements of Revolution Medicines, Warrant, assuming nothing else is changed. The correlation between historical values of Revolution Medicines,'s Ebit and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Revolution Medicines, Warrant are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Ebit i.e., Revolution Medicines,'s Ebit and Research Development go up and down completely randomly.

Correlation Coefficient

-0.93

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Ebit

Research Development

Most indicators from Revolution Medicines,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Revolution Medicines, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines, Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Sales General And Administrative To Revenue is likely to climb to 6.86 in 2024, whereas Tax Provision is likely to drop (3.7 M) in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	929K	9.2M	47.5M	49.9M
Net Interest Income	917K	9.2M	47.2M	49.5M

Interest Income Net Interest Income

Revolution Medicines, fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Good Will	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Non Current Liabilities Other	Net Working Capital	Intangible Assets	Short Long Term Debt Total
Total Assets		1.0	0.93	1.0	0.85	-0.98	0.98	0.99	0.86	0.15	-0.98	-0.91	0.92	1.0	0.74	0.84	1.0	0.9	0.99	0.85	1.0	-0.78	0.62	1.0	-0.88	0.89
Other Current Liab	1.0		0.92	1.0	0.86	-0.98	0.97	0.99	0.87	0.11	-0.99	-0.89	0.92	1.0	0.76	0.85	0.99	0.9	1.0	0.87	1.0	-0.81	0.62	1.0	-0.87	0.89
Total Current Liabilities	0.93	0.92		0.93	0.64	-0.89	0.98	0.97	0.65	0.4	-0.87	-0.93	0.8	0.91	0.45	0.62	0.95	0.76	0.89	0.65	0.94	-0.54	0.67	0.93	-0.83	0.72
Total Stockholder Equity	1.0	1.0	0.93		0.85	-0.98	0.98	0.99	0.86	0.16	-0.98	-0.91	0.92	1.0	0.74	0.84	1.0	0.9	0.99	0.85	1.0	-0.77	0.63	1.0	-0.88	0.89
Property Plant And Equipment Net	0.85	0.86	0.64	0.85		-0.91	0.74	0.78	1.0	-0.29	-0.92	-0.56	0.96	0.87	0.92	1.0	0.84	0.95	0.9	1.0	0.84	-0.93	0.43	0.84	-0.63	0.97
Retained Earnings	-0.98	-0.98	-0.89	-0.98	-0.91		-0.95	-0.96	-0.91	-0.04	0.99	0.83	-0.95	-0.98	-0.77	-0.89	-0.98	-0.93	-0.98	-0.91	-0.98	0.81	-0.55	-0.98	0.84	-0.94
Accounts Payable	0.98	0.97	0.98	0.98	0.74	-0.95		1.0	0.76	0.33	-0.93	-0.94	0.86	0.97	0.61	0.73	0.98	0.84	0.95	0.75	0.98	-0.63	0.68	0.98	-0.87	0.83
Cash	0.99	0.99	0.97	0.99	0.78	-0.96	1.0		0.8	0.27	-0.95	-0.93	0.89	0.98	0.66	0.77	0.99	0.87	0.97	0.79	0.99	-0.7	0.68	0.99	-0.87	0.85
Non Current Assets Total	0.86	0.87	0.65	0.86	1.0	-0.91	0.76	0.8		-0.26	-0.92	-0.6	0.95	0.89	0.95	1.0	0.85	0.94	0.91	0.99	0.85	-0.92	0.43	0.86	-0.67	0.97
Non Currrent Assets Other	0.15	0.11	0.4	0.16	-0.29	-0.04	0.33	0.27	-0.26		0.03	-0.42	-0.07	0.11	-0.31	-0.32	0.16	-0.01	0.03	-0.28	0.17	0.49	0.58	0.16	-0.15	-0.08
Net Receivables	-0.98	-0.99	-0.87	-0.98	-0.92	0.99	-0.93	-0.95	-0.92	0.03		0.83	-0.95	-0.99	-0.8	-0.91	-0.98	-0.92	-1.0	-0.92	-0.98	0.87	-0.53	-0.98	0.85	-0.93
Good Will	-0.91	-0.89	-0.93	-0.91	-0.56	0.83	-0.94	-0.93	-0.6	-0.42	0.83		-0.67	-0.89	-0.49	-0.55	-0.91	-0.64	-0.86	-0.57	-0.91	0.52	-0.54	-0.91	0.95	-0.66
Common Stock Shares Outstanding	0.92	0.92	0.8	0.92	0.96	-0.95	0.86	0.89	0.95	-0.07	-0.95	-0.67		0.93	0.82	0.94	0.92	0.99	0.94	0.96	0.92	-0.84	0.63	0.92	-0.65	0.95
Short Term Investments	1.0	1.0	0.91	1.0	0.87	-0.98	0.97	0.98	0.89	0.11	-0.99	-0.89	0.93		0.77	0.86	0.99	0.91	1.0	0.88	1.0	-0.81	0.6	1.0	-0.87	0.91
Non Current Liabilities Total	0.74	0.76	0.45	0.74	0.92	-0.77	0.61	0.66	0.95	-0.31	-0.8	-0.49	0.82	0.77		0.94	0.7	0.85	0.79	0.92	0.73	-0.88	0.35	0.74	-0.58	0.9
Capital Lease Obligations	0.84	0.85	0.62	0.84	1.0	-0.89	0.73	0.77	1.0	-0.32	-0.91	-0.55	0.94	0.86	0.94		0.82	0.94	0.89	1.0	0.83	-0.94	0.41	0.83	-0.63	0.96
Other Current Assets	1.0	0.99	0.95	1.0	0.84	-0.98	0.98	0.99	0.85	0.16	-0.98	-0.91	0.92	0.99	0.7	0.82		0.89	0.99	0.84	1.0	-0.76	0.62	1.0	-0.88	0.88
Total Liab	0.9	0.9	0.76	0.9	0.95	-0.93	0.84	0.87	0.94	-0.01	-0.92	-0.64	0.99	0.91	0.85	0.94	0.89		0.91	0.95	0.9	-0.8	0.69	0.9	-0.61	0.96
Net Invested Capital	0.99	1.0	0.89	0.99	0.9	-0.98	0.95	0.97	0.91	0.03	-1.0	-0.86	0.94	1.0	0.79	0.89	0.99	0.91		0.9	0.99	-0.85	0.57	0.99	-0.86	0.91
Property Plant And Equipment Gross	0.85	0.87	0.65	0.85	1.0	-0.91	0.75	0.79	0.99	-0.28	-0.92	-0.57	0.96	0.88	0.92	1.0	0.84	0.95	0.9		0.84	-0.92	0.44	0.85	-0.63	0.97
Total Current Assets	1.0	1.0	0.94	1.0	0.84	-0.98	0.98	0.99	0.85	0.17	-0.98	-0.91	0.92	1.0	0.73	0.83	1.0	0.9	0.99	0.84		-0.76	0.64	1.0	-0.88	0.89
Capital Stock	-0.78	-0.81	-0.54	-0.77	-0.93	0.81	-0.63	-0.7	-0.92	0.49	0.87	0.52	-0.84	-0.81	-0.88	-0.94	-0.76	-0.8	-0.85	-0.92	-0.76		-0.23	-0.77	0.65	-0.82
Non Current Liabilities Other	0.62	0.62	0.67	0.63	0.43	-0.55	0.68	0.68	0.43	0.58	-0.53	-0.54	0.63	0.6	0.35	0.41	0.62	0.69	0.57	0.44	0.64	-0.23		0.63	-0.29	0.52
Net Working Capital	1.0	1.0	0.93	1.0	0.84	-0.98	0.98	0.99	0.86	0.16	-0.98	-0.91	0.92	1.0	0.74	0.83	1.0	0.9	0.99	0.85	1.0	-0.77	0.63		-0.88	0.89
Intangible Assets	-0.88	-0.87	-0.83	-0.88	-0.63	0.84	-0.87	-0.87	-0.67	-0.15	0.85	0.95	-0.65	-0.87	-0.58	-0.63	-0.88	-0.61	-0.86	-0.63	-0.88	0.65	-0.29	-0.88		-0.69
Short Long Term Debt Total	0.89	0.89	0.72	0.89	0.97	-0.94	0.83	0.85	0.97	-0.08	-0.93	-0.66	0.95	0.91	0.9	0.96	0.88	0.96	0.91	0.97	0.89	-0.82	0.52	0.89	-0.69

Click cells to compare fundamentals

Revolution Medicines, Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Revolution Stock Analysis

When running Revolution Medicines,'s price analysis, check to measure Revolution Medicines,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines, is operating at the current time. Most of Revolution Medicines,'s value examination focuses on studying past and present price action to predict the probability of Revolution Medicines,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines,'s price. Additionally, you may evaluate how the addition of Revolution Medicines, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Revolution Ebit vs Research Development Analysis

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

Correlation Coefficient

Ebit

Research Development

Revolution Medicines, fundamental ratios Correlations

Revolution Medicines, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Revolution Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Liab	+ 1.0	Total Assets
Total Stockholder Equity	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets

Net Invested Capital	- 1.0	Net Receivables
Short Term Investments	- 0.99	Net Receivables
Net Receivables	- 0.99	Other Current Liab
Net Working Capital	- 0.98	Net Receivables
Total Current Assets	- 0.98	Net Receivables
Other Current Assets	- 0.98	Net Receivables